You are invited to take part in a research study that aims to understand how genes influence the risk of developing obsessive-compulsive disorder (OCD) in Latin American individuals.

Participation in this study involves completing a comprehensive assessment and providing a saliva sample. The one-time assessment visit will occur virtually over Zoom and ask about your OCD symptoms as well as psychological and social functioning. The saliva sample kit will be mailed to you to send back via pre-paid post.

This is not a treatment study. Participation in this study is completely voluntary and involves minimal risk. There is no anticipated direct benefit to you. However, your participation will provide the researchers with valuable information that may change the way we understand and treat OCD. This in turn may benefit future individuals and families.

You will receive your choice of a $50 e-gift card (, or for providing the saliva sample and completing the assessment.

Please know that your decision to take part (or not take part) in this study will not affect your current or future relationship with the University of Calgary, your current care provider or with any institution.


Currently recruiting participants: No

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 7 to 89

Accepts healthy participants: Yes

Inclusion criteria:

1. 7-89 years of age
2. Latin American, Hispanic, or Brazilian descent (at least one grandparent identifies as Latino or Hispanic)
3. have experienced OCD symptoms now or in the past
4. resident of Alberta
5. proficient in written and spoken English
6. access to computer/laptop with reliable internet
7. Parental consent is required if aged 7 - 17

Exclusion criteria:

Individuals who lack the capacity to provide assent (ages 7-17) or informed consent are not eligible for this study. Parental consent is required for children / adolescents aged 7-17.


Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

Principal investigator:

Paul Arnold

Clinical trial: